ArticleAmerican journal of translational research2025
Long intergenic non-protein coding RNA 1949 suppresses rituximab resistance in diffuse large B-cell lymphoma via H3K27me3-mediated ONECUT2 silencing.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of long non-coding RNA LINC01949 in mediating rituximab sensitivity and its underlying epigenetic mechanisms.
methodsExpression of LINC01949 was analyzed in rituximab-sensitive and -resistant diffuse large B-cell lymphoma (DLBCL) cell lines using Gene Expression Omnibus datasets. Functional assays involved LINC01949 knockdown in sensitive cells and overexpression in resistant cells, followed by evaluation of drug response (IC50, apoptosis) and protein levels. Mechanistic studies examined H3K27me3 modification and one cut homeobox 2(ONECUT2) expression. Rescue experiments employed H3K27me3 demethylase inhibitor (GSK-J4) and ONECUT2 inhibitor (CSRM617). EZH2 binding to LINC01949 was assessed by RIP-qPCR.
resultsLINC01949 expression was significantly downregulated in rituximab-resistant cells. Its knockdown in sensitive cells conferred resistance, while overexpression in resistant cells restored sensitivity. Mechanistically, LINC01949 loss reduced H3K27me3 levels, leading to derepression of the oncogenic transcription factor ONECUT2. Pharmacological restoration of H3K27me3 or inhibition of ONECUT2 reversed resistance. RIP-qPCR confirmed direct binding of LINC01949 to EZH2, which was diminished in resistant cells.
conclusionLINC01949 suppresses rituximab resistance in DLBCL by promoting H3K27me3-dependent silencing of ONECUT2. These findings highlight the LINC01949-H3K27me3-ONECUT2 axis as a key epigenetic pathway and suggest potential targets to overcome resistance in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.